Challenges in Assessing Outcomes among Infants of Pregnant HIV-Positive Women Receiving ART in Uganda

Table 1

Baseline and follow-up characteristics of the 700 women enrolled in the HIV-antenatal integrated clinic and retained into care up to the end of the pregnancy.

Characteristics	Total; (100%)	Infant tested; (80.7%)	Infant not tested; (19.3%)	value
Age (years), median (IQR)	31 (26–35)	31 (26–35)	28 (24–34)	0.03
Stage of pregnancy, (%)
1st trimester	233 (33.3)	187 (33.1)	46 (34.1)	0.87
2nd trimester	301 (43.0)	242 (42.8)	59 (43.7)
3rd trimester	153 (21.9)	125 (22.1)	28 (20.7)
On delivery	3 (0.4)	2 (0.4)	1 (0.7)
After birth	10 (1.4)	9 (1.6)	1 (0.7)
WHO clinical stage 3/4, (%)	254 (36.3)	204 (36.1)	50 (37.0)	0.84
Parity > 2, (%)	329 (39.5)	239 (43.6)	51 (38.1)	0.24
CD4 cells/µL, median (IQR) (%)	447 (301–651)	459 (307–658)	529 (277–593)	0.14
≤350	234 (33.5)	186 (33.0)	48 (35.6)	0.09
351–500	167 (23.9)	127 (22.6)	40 (29.6)
>500	297 (42.6)	250 (44.4)	47 (34.8)
Already on ART, (%)	513 (73.3)	418 (74.0)	95 (70.4)	0.39
Feeding option, breastfeeding	590 (85.1%)	491 (87.7%)	99 (74%)	<0.001
Follow up status, (%)
Retained	655 (93.6%)	558 (98.8)	97 (71.8)	<0.001
Dead	3 (0.4%)	0 (0.0)	3 (2.2)
Lost	18 (2.6%)	4 (0.7)	14 (10.4)
Transferred out	24 (3.4%)	3 (0.5)	21 (15.6)

; ART: antiretroviral treatment.